These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25226384)

  • 21. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
    Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
    Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
    Jelsing J; Vrang N; van Witteloostuijn SB; Mark M; Klein T
    J Endocrinol; 2012 Sep; 214(3):381-7. PubMed ID: 22761275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans.
    Fuchs H; Tillement JP; Urien S; Greischel A; Roth W
    J Pharm Pharmacol; 2009 Jan; 61(1):55-62. PubMed ID: 19126297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin AT1 receptor activation mediates high glucose-induced epithelial-mesenchymal transition in renal proximal tubular cells.
    Zhou L; Xue H; Yuan P; Ni J; Yu C; Huang Y; Lu LM
    Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):e152-7. PubMed ID: 20590668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
    Fuchs H; Runge F; Held HD
    Eur J Pharm Sci; 2012 Apr; 45(5):533-8. PubMed ID: 22198311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin.
    Zeisberg M; Zeisberg EM
    Kidney Int; 2015 Sep; 88(3):429-31. PubMed ID: 26323066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
    Lai ZW; Li C; Liu J; Kong L; Wen X; Sun H
    Eur J Med Chem; 2014 Aug; 83():547-60. PubMed ID: 24996141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
    Lietzau G; Davidsson W; Östenson CG; Chiazza F; Nathanson D; Pintana H; Skogsberg J; Klein T; Nyström T; Darsalia V; Patrone C
    Acta Neuropathol Commun; 2018 Feb; 6(1):14. PubMed ID: 29471869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease.
    Siddiqui N; Ali J; Parvez S; Zameer S; Najmi AK; Akhtar M
    Neuropharmacology; 2021 Sep; 195():108662. PubMed ID: 34119519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dipeptidyl peptidase-4 inhibitor linagliptin exhibits time- and dose-dependent localization in kidney, liver, and intestine after intravenous dosing: results from high resolution autoradiography in rats.
    Greischel A; Binder R; Baierl J
    Drug Metab Dispos; 2010 Sep; 38(9):1443-8. PubMed ID: 20538719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
    Terawaki Y; Nomiyama T; Kawanami T; Hamaguchi Y; Takahashi H; Tanaka T; Murase K; Nagaishi R; Tanabe M; Yanase T
    Cardiovasc Diabetol; 2014 Nov; 13():154. PubMed ID: 25407968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
    Barnett AH
    Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.